NM_001148.6:c.3572G>A
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_001148.6(ANK2):c.3572G>A(p.Arg1191Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000223 in 1,613,864 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001148.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152162Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 249900Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135176
GnomAD4 exome AF: 0.0000219 AC: 32AN: 1461702Hom.: 0 Cov.: 31 AF XY: 0.0000234 AC XY: 17AN XY: 727152
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152162Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74330
ClinVar
Submissions by phenotype
not specified Uncertain:1
Variant summary: The ANK2 c.3572G>A (p.Arg1191Gln) variant involves the alteration of a conserved nucleotide located in the ZU5 domain (IPR000906). 3/4 in silico tools predict a damaging outcome for this variant. This variant was found in 7/275606 control chromosomes in gnomAD at a frequency of 0.0000254, which is approximately 3 times the estimated maximal expected allele frequency of a pathogenic ANK2 variant (0.00001), suggesting this variant is likely a benign polymorphism. Multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. The variant of interest has not, to our knowledge, been reported in affected individuals via publications nor evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as VUS - possibly benign variant until addiitonal evidence becomes available. -
not provided Uncertain:1
p.Arg1191Gln (CGG>CAG): c.3572 G>A in exon 30 of the ANK2 gene (NM_001148.4). The Arg1191Gln variant in the ANK2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Arg1191Gln results in a semi-conservative amino acid substitution of positively charged Arginine with a neutral, polar Glutamine at a position that is conserved across species. In silico analysis predicts Arg1191Gln is damaging to the protein structure/function. The Arg1191Gln variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. However, no mutations in nearby residues have been reported in association with LQTS. With the clinical and molecular information available at this time, we cannot definitively determine if Arg1191Gln is a disease-causing mutation or a rare benign variant. The variant is found in LQT panel(s). -
Long QT syndrome Uncertain:1
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1191 of the ANK2 protein (p.Arg1191Gln). This variant is present in population databases (rs780110299, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with ANK2-related conditions. ClinVar contains an entry for this variant (Variation ID: 190567). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ANK2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The p.R1191Q variant (also known as c.3572G>A), located in coding exon 30 of the ANK2 gene, results from a G to A substitution at nucleotide position 3572. The arginine at codon 1191 is replaced by glutamine, an amino acid with highly similar properties. This variant was reported in a large pediatric neurodevelopmental delay cohort; however, clinical details were limited (Wang T et al. Nat Commun, 2020 10;11:4932). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. According to data from gnomAD, the frequency for this variant is above the maximum credible frequency for a cardiac disease-causing variant in this gene based on internally established thresholds (Karczewski et al. Nature. 2020 May;581(7809):434-443; Whiffin et al. Genet Med. 2017 10;19:1151-1158). Based on the supporting evidence, the association of this alteration with ANK2-related neurodevelopmental disorder is unknown; however, the association with ANK2-related arrhythmia is unlikely. -
Cardiac arrhythmia, ankyrin-B-related Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at